Compare Citius Pharmaceuticals Inc (CTXR) vs Select Medical Holdings Corporation (SEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Select Medical Holdings Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Select Medical Holdings Corporation trades at $16.51 (market cap $2.05B). The key difference: Select Medical Holdings Corporation is far larger — about 140× Citius Pharmaceuticals Inc's market cap, and Select Medical Holdings Corporation pays a 1.51% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | SEM | |
|---|---|---|
Market Cap | $14.64M | $2.05B |
Sector | Health | Health |
52-Week High | $1.82 | $16.66 |
52-Week Low | $0.53 | $11.77 |
Enterprise Value | $10.86M | $5.01B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Select Medical Holdings (SEM) trades at $16.51, unchanged on the day, following its recent acquisition completion by a consortium led by Robert A. Ortenzio and Martin F. announced on June 30, 2026. The stock shows mixed signals with a bullish overall technical outlook but bearish moving averages, while fundamentals indicate modest profitability with a net income margin of 2.42% and a P/E ratio of 15.43. Recent earnings have been inconsistent, with Q1 2026 missing expectations.
The acquisition at $16.50 per share caps near-term upside, with legal investigations into board fiduciary duties posing reputational risks. Analyst sentiment is neutral with a 57.15% hold rating, reflecting uncertainty post-buyout. Investors face limited growth prospects amid stable revenues and margin pressures, emphasizing caution in the current holding pattern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Select Medical Holdings Corporation
Select Medical Holdings Corporation is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. The company's services focus on treating patients with serious illnesses, injuries, and post-acute care needs. SEM provides specialized care across various settings, aiming to help patients recover and return home.
Read more on SEM →
